Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: Findings from an outpatient clinic setting

Metabolic Syndrome and Related Disorders

Volumn 10, Issue 3, 2012, Pages 189-194

  Ramachandran, Sud ^a   Abbas, Ahmed ^b   Saraf, Sanjay ^b   Raju, Jessie ^a   Jewkes, Christina ^a   Jones, Alan F ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; OUTPATIENT DEPARTMENT; PREMEDICATION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; ENGLAND; FACTOR ANALYSIS, STATISTICAL; FEMALE; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84861744519     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0112     Document Type: Article

References (28)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. Am J Med 1951;11:480-485.
2. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714. (Pubitemid 8110784)
3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
5. Barter P, Gotto AM, LaRosa JC, et al. and the Treating to New Target Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310. (Pubitemid 47481452)
6. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease. Circulation 2007;115:450-458.
7. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144-53.
8. Kontush A, Guérin M, Chapman MJ. Spotlight on HDLraising therapies: Insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008;5:329-36. (Pubitemid 351761707)
9. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary Heart disease. J Am Coll Cardiol 2010;55:1283-1299.
10. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005:96:1221-1232. (Pubitemid 40962099)
11. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093. (Pubitemid 28512236)
12. Chapman MJ. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13. (Pubitemid 37474095)
13. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: Mechanism of action and clinical efficacy. Curr Atherosclerosis Rep 2004;6:148-57.
14. Auwerx J, Schoonjans K, Fruchart JC, et al. Regulation of triglyceride metabolism by PPARs: Fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 1996;3:81-89.
15. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: Mechanisms of action and rational prescribing. Vasc Health Risk Manag 2008;4:991-1000.
16. KornitzerM,DramaixM, VandenbroekMD, et al. Efficacy and tolerance of 200mgmicronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter study. Atherosclerosis 1994;110(Suppl):S49-S54.
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
18. Shepherd J, Cobbe SM, Ford I, et al. for the WOSCPS Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-1308.
19. Ridker PM, Danielson E, Fonseca FA, et al. for JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
20. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563-1574.
21. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: Experience from the Helsinki Heart Study. Circulation 1995;92:1779-1785.
22. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162: 2597-2604. (Pubitemid 35453499)
23. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention ofmyocardial infarction in patientswith metabolic syndrome. Arch Intern Med 2005;165:1154-1160. (Pubitemid 40720740)
24. Scott R, O'Brien R, Fulcher G, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32:493-498.
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735-2752.
26. Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effects of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER database. J Lipid Res 2010;51:1546-1553.
27. Barter PJ, Rye KA. Cardioprotective properties of fibrates: Which fibrate, which patients, what mechanism? Circulation 2006;113;1553-1555. (Pubitemid 43739413)
28. Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: A call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5:319-335.